Ultragenyx Cuts 20% of Staff, Ends Programs
The biotech company is halving its annual R&D budget after setbacks in its drug pipeline and a shift toward growing sales of commercial products.
Updated on Nov. 4, 2026 in Biotech
Ultragenyx laid off 20% of its workforce and ended several drug development programs to halve its annual R&D budget. The company disclosed the deeper-than-expected cuts after the market closed on Tuesday.
Why it matters
The reductions are aimed at making Ultragenyx profitable in 2027 after recent R&D setbacks trimmed its investigational drug pipeline. The company is shifting its focus toward growing sales of its six commercial products.
Ultragenyx ended 2025 with 1,371 employees, 916 of them in R&D, and the February 10% reduction affected about 130 staff. The company's proposed 2027 R&D budget is $350 million, with most of it earmarked for commercial products.
The players
Ultragenyx
Ultragenyx is a biopharmaceutical company focused on rare genetic diseases, with six commercial products and a pipeline that has recently been reduced after clinical setbacks.
The details
Ultragenyx is winding down all ongoing studies of GTX-102 and ending development of UX701 for Wilson disease. Setrusumab failed a pair of phase 3 trials late last year, and the company is also reducing its real estate footprint as part of its cost-containment strategy.
Timeline
February 2026: Ultragenyx forecast an R&D decline and implemented a 10% workforce reduction.
September 2026: The phase 3 Angelman syndrome trial of GTX-102 failed.
Tuesday, November 3, 2026: Ultragenyx disclosed deeper cuts after the market close.
2026: The workforce reduction to about 1,000 staff is expected to be largely completed.
2027: Target year for profitability and the proposed $350 million R&D budget.
Tech Race
The cuts extend the February reduction that Ultragenyx announced in its 2026 R&D forecast, deepening it from 10% to 20% of the workforce. The company is following a pattern of pipeline pruning in favor of commercial products as it pursues profitability by 2027.
For patients with rare genetic diseases, the narrowing of Ultragenyx's pipeline means some investigational treatments, including GTX-102 and UX701, will no longer be advanced by the company. The focus shifts to the six commercial products already on the market.
The takeaway
Biotech companies facing pipeline setbacks are increasingly prioritizing commercial products and cost discipline over early-stage research. Ultragenyx's push toward profitability in 2027 illustrates how that trade-off is playing out in practice.
What happens next
Ultragenyx expects to largely complete the 20% workforce reduction this year, and its DTX301 phase 3 results in ornithine transcarbamylase deficiency are due next year.
Further reading
Explore more Biotech coverage for context on how drugmakers are reshaping their pipelines.
